Potential harmful effects of discontinuing ace-inhibitors and arbs in covid-19 patients

eLife

Volumn 9, Issue , 2020, Pages

  Rossi, Gian Paolo ^a   Sanga, Viola ^a   Barton, Matthias ^b,c  

^a UNIVERSITY OF PADOVA   (Italy)

^b UNIVERSITY OF ZURICH   (Switzerland)

^c Andreas Grüntzig Foundation   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANGIOTENSIN CONVERTING ENZYME 1; ANGIOTENSIN CONVERTING ENZYME 2; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; PEPTIDES AND PROTEINS; RECOMBINANT ANGIOTENSIN CONVERTING ENZYME 2; RECOMBINANT PROTEIN; UNCLASSIFIED DRUG; VIRUS SPIKE PROTEIN; ACE PROTEIN, HUMAN; ANGIOTENSIN RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE; PROTECTIVE AGENT;

ADULT RESPIRATORY DISTRESS SYNDROME; ARTICLE; CORONAVIRUS DISEASE 2019; DISEASE COURSE; DISEASE PREDISPOSITION; DRUG SUBSTITUTION; DRUG WITHDRAWAL; HEART FAILURE; HEART INFARCTION; HEART PROTECTION; HUMAN; INTENSIVE CARE UNIT; RENAL PROTECTION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2; VIRUS PNEUMONIA; VIRUS VIRULENCE; BETACORONAVIRUS; CORONAVIRUS INFECTION; DRUG EFFECT; LUNG; METABOLISM; PANDEMIC; VIROLOGY;

ANGIOTENSIN RECEPTOR ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; BETACORONAVIRUS; CORONAVIRUS INFECTIONS; LUNG; PANDEMICS; PEPTIDYL-DIPEPTIDASE A; PNEUMONIA, VIRAL; PROTECTIVE AGENTS; RENIN-ANGIOTENSIN SYSTEM;

EID: 85083282531     PISSN: None     EISSN: 2050084X     Source Type: Journal    
DOI: 10.7554/eLife.57278     Document Type: Article

References (42)

1. Bozkurt B, Kovacs R, Harrington B. 2020. HFSA/ACC/AHA Statement Addresses Concerns Re: Using RAAS Antagonists in COVID-19: American College of Cardiology. https://www.acc.org/latest-in-cardiology/articles/2020/03/17/08/59/hfsa-acc-aha-statement-addresses-concerns-re-using-raas-antagonists-in-COVID-19.
2. Burrell LM, Risvanis J, Kubota E, Dean RG, MacDonald PS, Lu S, Tikellis C, Grant SL, Lew RA, Smith AI, Cooper ME, Johnston CI. 2005. Myocardial infarction increases ACE2 expression in rat and humans. European Heart Journal 26:369–375. DOI: https://doi.org/10.1093/eurheartj/ehi114, PMID: 15671045
3. Caldeira D, Alarcão J, Vaz-Carneiro A, Costa J. 2012. Risk of pneumonia associated with use of angiotensin converting enzyme inhibitors and angiotensin receptor blockers: systematic review and meta-analysis. BMJ 345:e4260. DOI: https://doi.org/10.1136/bmj.e4260, PMID: 22786934
4. Cao Y, Liu Y, Shang J, Yuan Z, Ping F, Yao S, Guo Y, Li Y. 2019. Ang-(1-7) Treatment attenuates lipopolysaccharide-Induced early pulmonary fibrosis. Nature 99:1770–1783. DOI: https://doi.org/10.1038/s41374-019-0289-7
5. Danser AHJ, Epstein M, Batlle D. 2020. Renin-angiotensin system blockers and the COVID-19 pandemic: at present there is no evidence to abandon renin-angiotensin system blockers. Hypertension 75:15082. DOI: https://doi.org/10.1161/HYPERTENSIONAHA.120.15082
6. Dhawale VS, Amara VR, Karpe PA, Malek V, Patel D, Tikoo K. 2016. Activation of angiotensin-converting enzyme 2 (ACE2) attenuates allergic airway inflammation in rat asthma model. Toxicology and Applied Pharmacology 306:17–26. DOI: https://doi.org/10.1016/j.taap.2016.06.026, PMID: 27343405
7. European Medicines Agency. 2020. EMA Advises Continued Use of Medicines for Hypertension, Heart or Kidney Disease During COVID-19 Pandemic: EMA. https://www.ema.europa.eu/en/news/ema-advises-continued-use-medicines-hypertension-heart-kidney-disease-during-covid-19-pandemic.
8. Fang L, Karakiulakis G, Roth M. 2020. Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection? The Lancet Respiratory Medicine 8:30116. DOI: https://doi.org/10.1016/S2213-2600(20) 30116-8, PMID: 32171062
9. Greene SJ, Gheorghiade M, Vaduganathan M, Ambrosy AP, Mentz RJ, Subacius H, Maggioni AP, Nodari S, Konstam MA, Butler J, Filippatos G, EVEREST Trial investigators. 2013. Haemoconcentration, renal function, and post-discharge outcomes among patients hospitalized for heart failure with reduced ejection fraction: insights from the EVEREST trial. European Journal of Heart Failure 15:1401–1411. DOI: https://doi.org/10. 1093/eurjhf/hft110, PMID: 23845795
10. Hamming I, Timens W, Bulthuis ML, Lely AT, Navis G, van Goor H. 2004. Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus a first step in understanding SARS pathogenesis. The Journal of Pathology 203:631–637. DOI: https://doi.org/10.1002/path.1570, PMID: 15141377
11. Harmer D, Gilbert M, Borman R, Clark KL. 2002. Quantitative mRNA expression profiling of ACE 2, a novel homologue of angiotensin converting enzyme. FEBS Letters 532:107–110. DOI: https://doi.org/10.1016/S0014-5793(02)03640-2, PMID: 12459472
12. Heurich A, Hofmann-Winkler H, Gierer S, Liepold T, Jahn O, Pöhlmann S. 2014. TMPRSS2 and ADAM17 cleave ACE2 differentially and only proteolysis by TMPRSS2 augments entry driven by the severe acute respiratory syndrome coronavirus spike protein. Journal of Virology 88:1293–1307. DOI: https://doi.org/10.1128/JVI. 02202-13, PMID: 24227843
13. Hoffmann M, Kleine-Weber H, Schroeder S, Krüger N, Herrler T, Erichsen S, Schiergens TS, Herrler G, Wu NH, Nitsche A, Müller MA, Drosten C, Pöhlmann S. 2020. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell 181:271–280. DOI: https://doi.org/10.1016/j.cell. 2020.02.052, PMID: 32142651
14. Imai Y, Kuba K, Rao S, Huan Y, Guo F, Guan B, Yang P, Sarao R, Wada T, Leong-Poi H, Crackower MA, Fukamizu A, Hui CC, Hein L, Uhlig S, Slutsky AS, Jiang C, Penninger JM. 2005. Angiotensin-converting enzyme 2 protects from severe acute lung failure. Nature 436:112–116. DOI: https://doi.org/10.1038/nature03712, PMID: 16001071
15. Imai Y, Kuba K, Penninger JM. 2008. The discovery of angiotensin-converting enzyme 2 and its role in acute lung injury in mice. Experimental Physiology 93:543–548. DOI: https://doi.org/10.1113/expphysiol.2007.040048, PMID: 18448662
16. Ishiyama Y, Gallagher PE, Averill DB, Tallant EA, Brosnihan KB, Ferrario CM. 2004. Upregulation of angiotensin-converting enzyme 2 after myocardial infarction by blockade of angiotensin II receptors. Hypertension 43:970–976. DOI: https://doi.org/10.1161/01.HYP.0000124667.34652.1a, PMID: 15007027
17. Jia HP, Look DC, Shi L, Hickey M, Pewe L, Netland J, Farzan M, Wohlford-Lenane C, Perlman S, McCray PB. 2005. ACE2 receptor expression and severe acute respiratory syndrome coronavirus infection depend on differentiation of human airway epithelia. Journal of Virology 79:14614–14621. DOI: https://doi.org/10.1128/JVI.79.23.14614-14621.2005, PMID: 16282461
18. Kaparianos A, Argyropoulou E. 2011. Local renin-angiotensin II systems, angiotensin-converting enzyme and its homologue ACE2: their potential role in the pathogenesis of chronic obstructive pulmonary diseases, pulmonary hypertension and acute respiratory distress syndrome. Current Medicinal Chemistry 18:3506–3515. DOI: https://doi.org/10.2174/092986711796642562, PMID: 21756232
19. Khan A, Benthin C, Zeno B, Albertson TE, Boyd J, Christie JD, Hall R, Poirier G, Ronco JJ, Tidswell M, Hardes K, Powley WM, Wright TJ, Siederer SK, Fairman DA, Lipson DA, Bayliffe AI, Lazaar AL. 2017. A pilot clinical trial of recombinant human angiotensin-converting enzyme 2 in acute respiratory distress syndrome. Critical Care 21: 234–243. DOI: https://doi.org/10.1186/s13054-017-1823-x, PMID: 28877748
20. Kruse RL. 2020. Therapeutic strategies in an outbreak scenario to treat the novel coronavirus originating in Wuhan, China. F1000Research 9:72. DOI: https://doi.org/10.12688/f1000research.22211.2, PMID: 32117569
21. Kuba K, Imai Y, Rao S, Gao H, Guo F, Guan B, Huan Y, Yang P, Zhang Y, Deng W, Bao L, Zhang B, Liu G, Wang Z, Chappell M, Liu Y, Zheng D, Leibbrandt A, Wada T, Slutsky AS, et al. 2005. A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury. Nature Medicine 11:875–879. DOI: https://doi.org/10.1038/nm1267, PMID: 16007097
22. Kuba K, Imai Y, Penninger JM. 2006. Angiotensin-converting enzyme 2 in lung diseases. Current Opinion in Pharmacology 6:271–276. DOI: https://doi.org/10.1016/j.coph.2006.03.001, PMID: 16581295
23. Li XC, Zhang J, Zhuo JL. 2017. The vasoprotective axes of the renin-angiotensin system: physiological relevance and therapeutic implications in cardiovascular, hypertensive and kidney diseases. Pharmacological Research 125:21–38. DOI: https://doi.org/10.1016/j.phrs.2017.06.005, PMID: 28619367
24. Li R, Pei S, Chen B, Song Y, Zhang T, Yang W, Shaman J. 2020. Substantial undocumented infection facilitates the rapid dissemination of novel coronavirus (SARS-CoV2). Science 6:eabb3221. DOI: https://doi.org/10.1126/science.abb3221
25. Liu CL, Shau WY, Wu CS, Lai MS. 2012. Angiotensin-converting enzyme inhibitor/angiotensin II receptor blockers and pneumonia risk among stroke patients. Journal of Hypertension 30:2223–2229. DOI: https://doi.org/10. 1097/HJH.0b013e328357a87a, PMID: 22929610
26. Meng Y, Yu CH, Li W, Li T, Luo W, Huang S, Wu PS, Cai SX, Li X. 2014. Angiotensin-converting enzyme 2/ angiotensin-(1-7)/Mas axis protects against lung fibrosis by inhibiting the MAPK/NF-kB pathway. American Journal of Respiratory Cell and Molecular Biology 50:723–736. DOI: https://doi.org/10.1165/rcmb.2012-0451OC, PMID: 24168260
27. Ocaranza MP, Godoy I, Jalil JE, Varas M, Collantes P, Pinto M, Roman M, Ramirez C, Copaja M, Diaz-Araya G, Castro P, Lavandero S. 2006. Enalapril attenuates downregulation of angiotensin-converting enzyme 2 in the late phase of ventricular dysfunction in myocardial infarcted rat. Hypertension 48:572–578. DOI: https://doi.org/10.1161/01.HYP.0000237862.94083.45, PMID: 16908757
28. Perico L, Benigni A, Remuzzi G. 2020. Should COVID-19 concern nephrologists? why and to what extent? the emerging impasse of angiotensin blockade. Nephron 24126:1–9. DOI: https://doi.org/10.1159/000507305
29. Rubin EJ, Baden LR, Morrissey S. 2020. New research on possible treatments for COVID-19. The New England Journal of Medicine 382:e32. DOI: https://doi.org/10.1056/NEJMe2006742
30. Shinohara Y, Origasa H. 2012. Post-stroke pneumonia prevention by angiotensin-converting enzyme inhibitors: results of a meta-analysis of five studies in Asians. Advances in Therapy 29:900–912. DOI: https://doi.org/10. 1007/s12325-012-0049-1
31. Tan WSD, Liao W, Zhou S, Mei D, Wong WF. 2018. Targeting the renin–angiotensin system as novel therapeutic strategy for pulmonary diseases. Current Opinion in Pharmacology 40:9–17. DOI: https://doi.org/10.1016/j. coph.2017.12.002, PMID: 29288933
32. Vaduganathan M, Vardeny O, Michel T, McMurray JJV, Pfeffer MA, Solomon SD. 2020. Renin–angiotensin– aldosterone system inhibitors in patients with COVID-19. New England Journal of Medicine 382:1653–1659. DOI: https://doi.org/10.1056/NEJMsr2005760, PMID: 32227760
33. Wang HC, Lin CC, Lau CI, Chang A, Kao CH. 2015. Angiotensin-converting enzyme inhibitors and bacterial pneumonia in patients with parkinson disease. Movement Disorders 30:593–596. DOI: https://doi.org/10.1002/mds.26136, PMID: 25641619
34. Wösten-van Asperen RM, Lutter R, Specht PA, Moll GN, van Woensel JB, van der Loos CM, van Goor H, Kamilic J, Florquin S, Bos AP. 2011. Acute respiratory distress syndrome leads to reduced ratio of ACE/ACE2 activities and is prevented by angiotensin-(1-7) or an angiotensin II receptor antagonist. The Journal of Pathology 225: 618–627. DOI: https://doi.org/10.1002/path.2987, PMID: 22009550
35. Wrapp D, Wang N, Corbett KS, Goldsmith JA, Hsieh CL, Abiona O, Graham BS, McLellan JS. 2020. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science 367:1260–1263. DOI: https://doi.org/10.1126/science.abb2507, PMID: 32075877
36. Xu X, Chen P, Wang J, Feng J, Zhou H, Li X, Zhong W, Hao P. 2020. Evolution of the novel coronavirus from the ongoing wuhan outbreak and modeling of its spike protein for risk of human transmission. Science China Life Sciences 63:457–460. DOI: https://doi.org/10.1007/s11427-020-1637-5
37. Yamamoto M, Matsuyama S, Li X, Takeda M, Kawaguchi Y, Inoue JI, Matsuda Z. 2016. Identification of nafamostat as a potent inhibitor of middle east respiratory syndrome coronavirus S protein-mediated membrane fusion using the split-protein-based cell-cell fusion assay. Antimicrobial Agents and Chemotherapy 60:6532–6539. DOI: https://doi.org/10.1128/AAC.01043-16
38. Yan R, Zhang Y, Guo Y, Xia L, Zhou Q. 2020. Structural basis for the recognition of the 2019-nCoV by human ACE2. bioRxiv. DOI: https://doi.org/10.1101/2020.02.19.956946
39. Yang P, Gu H, Zhao Z, Wang W, Cao B, Lai C, Yang X, Zhang L, Duan Y, Zhang S, Chen W, Zhen W, Cai M, Penninger JM, Jiang C, Wang X. 2015. Angiotensin-converting enzyme 2 (ACE2) mediates influenza H7N9 virus-induced acute lung injury. Scientific Reports 4:7027. DOI: https://doi.org/10.1038/srep07027
40. Zhang H, Penninger JM, Li Y, Zhong N, Slutsky AS. 2020. Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: molecular mechanisms and potential therapeutic target. Intensive Care Medicine 46:586–590. DOI: https://doi.org/10.1007/s00134-020-05985-9, PMID: 32125455
41. Zheng Y-Y, Ma Y-T, Zhang J-Y, Xie X. 2020. COVID-19 and the cardiovascular system. Nature Reviews Cardiology 395:0360. DOI: https://doi.org/10.1038/s41569-020-0360-5
42. Zhou P, Yang XL, Wang XG, Hu B, Zhang L, Zhang W, Si HR, Zhu Y, Li B, Huang CL, Chen HD, Chen J, Luo Y, Guo H, Jiang RD, Liu MQ, Chen Y, Shen XR, Wang X, Zheng XS, et al. 2020. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature 579:270–273. DOI: https://doi.org/10.1038/s41586-020-2012-7, PMID: 32015507